A detailed history of Crewe Advisors LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Crewe Advisors LLC holds 3,412 shares of ABBV stock, worth $581,234. This represents 0.08% of its overall portfolio holdings.

Number of Shares
3,412
Previous 3,393 0.56%
Holding current value
$581,234
Previous $581,000 15.83%
% of portfolio
0.08%
Previous 0.07%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$163.84 - $199.33 $3,112 - $3,787
19 Added 0.56%
3,412 $673,000
Q2 2024

Jul 29, 2024

BUY
$154.79 - $180.76 $30,803 - $35,971
199 Added 6.23%
3,393 $581,000
Q1 2024

May 13, 2024

BUY
$159.82 - $182.1 $510,465 - $581,627
3,194 New
3,194 $581,000
Q2 2023

Jul 28, 2023

SELL
$132.51 - $164.9 $88,119 - $109,658
-665 Reduced 20.11%
2,642 $355,000
Q1 2023

May 12, 2023

SELL
$144.61 - $166.54 $1,879 - $2,165
-13 Reduced 0.39%
3,307 $527,000
Q4 2022

Feb 07, 2023

BUY
$138.31 - $165.87 $141,906 - $170,182
1,026 Added 44.73%
3,320 $536,000
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $115,823 - $132,841
863 Added 60.31%
2,294 $308,000
Q2 2022

Aug 02, 2022

BUY
$137.62 - $174.96 $183,172 - $232,871
1,331 Added 1331.0%
1,431 $219,000
Q4 2021

Feb 10, 2022

BUY
$107.43 - $135.93 $1,826 - $2,310
17 Added 20.48%
100 $14,000
Q4 2020

Jan 27, 2021

SELL
$80.49 - $108.67 $4,185 - $5,650
-52 Reduced 38.52%
83 $9,000
Q3 2020

Oct 13, 2020

BUY
$85.91 - $100.83 $11,597 - $13,612
135 New
135 $12,000
Q4 2018

Feb 05, 2019

SELL
$77.85 - $96.01 $5,838 - $7,200
-75 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$88.91 - $98.84 $13,336 - $14,826
-150 Reduced 66.67%
75 $7,000
Q2 2018

Aug 07, 2018

SELL
$89.78 - $106.23 $11,222 - $13,278
-125 Reduced 35.71%
225 $21,000
Q1 2018

May 07, 2018

BUY
$92.01 - $123.21 $32,019 - $42,877
348 Added 17400.0%
350 $33,000
Q4 2017

Feb 09, 2018

BUY
$89.56 - $98.21 $179 - $196
2
2 $0

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $301B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Crewe Advisors LLC Portfolio

Follow Crewe Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crewe Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Crewe Advisors LLC with notifications on news.